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 Authors’ reply
Wilson and colleagues  report 
important new information showing 
that most transgender women 
achieved protective concentrations of 
drugs in an open label pre-exposure 
prophylaxis (PrEP) demonstration 
project in Brazil. This is consistent with 
findings showing that effective use 
of PrEP is common in clinical practice 
and demonstration projects in diverse 
populations.1
Lack of access to gender-aﬃ  rming 
care is the most commonly cited 
barrier to health care for trans 
women.2,3 Gender-affirming care 
goes beyond hormone therapy to 
include clinic environments where 
chosen names and pronouns are 
respected, patients feel safe using 
the bathroom of their choice, and 
clinic staﬀ  have basic cultural ﬂ uency. 
Transgender women and their allies 
are advocating for gender affirming 
care around the world, including in 
Brazil.4 Furthermore, it is surprising 
that Wilson and colleagues assume 
that because only 52% of trans women 
in one survey were using hormones, 
the remaining 48% “may not be 
interested” in trans health services. 
Certainly not all trans women are 
interested in hormone therapy; 
however, the absence of health care 
that is gender aﬃ  rming, life instability, 
and poverty may limit access to 
hormones, especially among those 
most at risk for HIV, even in contexts 
where hormones are available without 
a prescription. 
In the iPrEx open label extension, 
PrEP drug concentrations were low 
PrEP adherence among 
trans women in Brazil—
access needed for this 
key population
The recent sub-analysis of iPrEx found 
that pre-exposure prophylaxis (PrEP) 
can be an effective HIV prevention 
tool for trans women.1 The iPrEx sub-
analysis found no seroconversions 
among trans women with detectable 
drug concentrations, but 70% of trans 
women in the sample were taking few 
or none of their PrEP pills. 
The researchers hypothesised that 
low adherence resulted from past 
experiences with providers or clinics 
that were unsupportive of transgender 
identities or concerns about hormone 
interactions. To address adherence 
issues, the authors recommend that 
PrEP be provided in gender-aﬃ  rming 
clinical settings that provide trans 
health services such as hormone 
therapy and sexual health services. 
We could not agree more with the 
call for culturally competent care for 
trans women. However, linking PrEP 
provision to trans health services 
might, in practice, limit access for 
many trans women.
HIV epidemics among trans women 
exist in many places where there are 
no trans health services, especially 
in low-income and middle-income 
countries.2 Even when available, many 
trans women may not be interested in 
such services. We found that only 52% 
of 345 trans women in a population-
based study in Rio de Janeiro were 
currently using hormones despite the 
ability to access hormones without 
a prescription. In fact, those most at 
risk for HIV were the least likely to use 
hormones. In another ongoing study we 
found evidence of positive adherence 
outcomes among trans women 
provided PrEP without trans health 
services. Trans health services were 
not provided as part of PrEP Brasil—a 
48 week multicentre, open-label, PrEP 
demonstration project to assess the 
feasibility of PrEP implementation 
among high-risk MSM and trans 
women in Brazil. In comparing drug 
concentrations between trans women 
and MSM, there was no significant 
diﬀ erence in adherence (p=0·49), and 
over 90% of trans women (n=25) had 
protective drug concentrations at 
4 weeks (72·7% with four or more doses 
per week, 18·2% with two to three 
doses per week detected). Adherence at 
4 weeks is signiﬁ cantly correlated with 
longer-term PrEP adherence.3
Trans women need immediate 
access to HIV prevention methods, 
including PrEP, to address the 
devastating burden of HIV they bear. 
Recommending PrEP be provided 
in combination with trans health 
services could stymie access for trans 
women in places where these services 
are not available. Or worse, in settings 
where trans identity is criminalised 
or punished, hinging PrEP to trans 
health services could create more 
risk than protection. The authors’ 
recommendation could also result in 
missing trans women at highest risk 
of HIV. Equally important, high PrEP 
adherence among trans women is 
possible without trans health services. 
Moving in parallel to increase access 
to PrEP immediately while working to 
improve access to trans health services 
might be the best strategy for meeting 
the HIV and health needs of trans 
women in low-income and middle-
income countries.  
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Advocating for PrEP provision with-
out striving for gender-aﬃ  rming care 
environ ments may excuse health 
systems from developing programmes 
for this marginalised and often invisible 
population. We are disappointed that 
PrEP Brasil, which was supported by 
two national governments and a global 
pharmaceutical company, did not 
provide trans health care. 
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among trans women who reported 
use of feminising hormones; whereas 
PrEP concentrations in trans women 
not using hormones and men were 
much the same.5 These findings 
supported our conclusion that 
participant concerns about PrEP 
interfering with hormone therapy 
might have contributed to less 
effective use of the intervention. 
Wilson and colleagues do not report 
any information about hormone use 
among the trans women enrolled 
in PrEP Brasil, and given the small 
numbers who were included (n=25), 
we think it premature to conclude 
that PrEP provided without gender 
aﬃ  rming services leads to acceptable 
outcomes for trans women in 
general.
